Belite Bio, Inc (BLTE) fair value analysis
Nasdaq · Updated 2026-10-19
BLTE price how computed
Valuation status
Awaiting full valuationBLTE's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once BLTE's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $142.78
- Sector
- Healthcare
- 12-month range
- $92.82–$193.61
- Market cap
- $5.75B
- From 52-week high
- -26.3%
- Shares outstanding
- 40.3M
- Rank in Healthcare by quality score
- #292 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, particularly age-related macular degeneration and other inherited retinal conditions. The company operates in the United States and conducts research and development activities for its pipeline of investigational drug candidates.
BLTE currently ranks #292 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $5.75B
- P/E (trailing)
- n/m
- EPS (TTM)
- $-2.73
- Shares outstanding
- 40.3M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 26 · oversold
- 50-day average
- $165.01
- 200-day average
- $160.84
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-09
- Last 8 quarters vs consensus
- 2 beat, 5 missed
- Quarter by quarter
- 2026-06 ▲ beat (+4.1%)
2026-03 ▼ miss (-6.3%)
2025-12 ▼ miss (-29.6%)
2025-09 ▼ miss (-32.7%)
2025-06 ▼ miss (-19.0%)
2025-03 ▼ miss (-25.0%)
2024-12 ▬ met (0.0%)
2024-09 ▲ beat (+6.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 9 buy · 0 hold · 0 sell (9 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $229
- Target vs last price
- +60.4%
What our data shows for BLTE
- Shares are trading in the middle of their 12-month price range of $92.82–$193.61.
- The 14-day relative strength index sits at an oversold 26.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- BLTE's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the BLTE conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for BLTE show mixed movement this week. The 50/200-day trend state shifted from uptrend to mixed, while the RSI zone moved from neutral to oversold. The current valuation verdict remains awaiting full valuation.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for BLTE show that the 50/200-day trend state has shifted from mixed to uptrend this week. The stock operates within the Healthcare sector and currently has a valuation verdict of awaiting full valuation. This change in trend state reflects a shift toward more positive short-term momentum relative to longer-term price movement.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is BLTE stock undervalued?
BLTE's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is BLTE's TickrTrends verdict?
BLTE is currently marked 'Awaiting full valuation' - a verdict publishes automatically once BLTE's own trailing P/E history validates under our standards.
How does BLTE compare to other Healthcare stocks?
BLTE ranks #292 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is BLTE overbought or oversold?
BLTE's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does BLTE report earnings next?
BLTE's next earnings report is scheduled for 2026-11-09, per the published earnings calendar.
Does BLTE usually beat earnings estimates?
Over its last 8 reported quarters BLTE beat the consensus estimate 2 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BLTE?
Of 9 analysts covering BLTE, 9 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $229 (+60.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.